Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Sunstar, I welcome the modest share price upswing. However, I don't read much into it. Peregrine obviously has upside potential from rapidly increasing Avid profitability alone.
If we see an exosome partnering announcement with millions of upfront cash, then maybe we'll see more significant share price movement. Soon would be nice.
GLTA, Paul
corp, nobody will buy Dios style shenanigans from Peregrine, and management must know it.
The RS is fully baked into the pathetic share price IMO. If there is a significant price drop with the RS, it might represent a scary, but potentially very rewarding trade for those with iron cojones. Not me. I'm done throwing any more money into Peregrine.
I like to think Peregrine will be able to keep Avid on the steep upward curve resulting in corporate profitability and a substantially higher share price.
If Bavi can earn FDA approval in some indications for some patients, maybe I'll even get back to even on this dreadful speculation.
GLTA, Paul
corp, I suggest "we" don't know what may happen before the RS. While Peregrine is unlikely to surprise us with a move back over 50 cents, it is by no stretch impossible. Maybe Halo will decide to buy out Peregrine at more than 50 cents a share to secure control over Avid.
We'll see.
GLTA, Paul
How much is the Avid business worth? Is the valuation based on gross earnings or net profits?
Could Peregrine spin off Avid and do an IPO?
GLTA, Paul
Enough looking back. What is in Peregrine headlights, besides the reverse split?
If Peregrine did report consecutive profitable quarters with revenue $80-100 million, could we see $1 per pre-RS share?
Any hope of Bavi clinical results in 2017?
I know all about the past. Boring!
GLTA, Paul
Not much point in debating about the RS. It will happen. Until it does the share price has little hope of rising.
I'd love to be wrong about this, but there is nothing on the horizon to stop it.
After the RS, PPHM shares will only move higher on seriously good news. Major money partner willing to invest serious money in Peregrine or several years of profitable quarters. I am basing my faint hopes on the latter.
GLTA, Paul
IFU, Peregrine's plan to
Cloaked, while your exuberance is entertaining, I'm afraid unbridled optimism in Peregrine's prospects has not worked out well for us. At least I know my wife would poison me if she knew about our "paper loss" on PPHM.
For the foreseeable future let's take Peregrine management's earnings estimates as our guide. Dreaming about international expansion and huge revenue increases is premature at best.
GLTA, Paul
Peregrine is not going to make us millionaires. Get over it. It was a nice dream, but reality in the form of clinical trials told us to wake up.
Meanwhile, Peregrine's Avid is a rapidly growing, highly profitable business. Let's see how fast it can grow and how profitable it can get.
Anti-PS may be worth something, but we have no proof yet. Maybe we never will. Keep the fingers crossed, but keep your eyes on Avid IMO.
GLTA, Paul
Now that hope for a positive outcome has vanished for all but the hardest of the hardcore maybe we will have a good year. Not a great, make us all rich year, but the kind of year where our shares are worth more than they are now.
GLTA, Paul
The end of a horrible year for Peregrine. Horrible, horrible, horrible. Next year could be just as bad. I like to think Avid will have a good year or two and restore some of our gigantic paper losses. Could be wrong.
I like to think Phil Thorpe's anti-PS discovery has commercial potential. Not yet. Maybe never.
So, here's to 2017. May it restore half of what we lost in 2016.
GLTA, Paul
Pumps and dumps? Please. Not that much drama here. Just a little company transitioning from delusions of grandeur to business as usual for a small, but rapidly growing bio-manufacturing company.
GLTA, Paul
geo, I think the share price collapse has convinced Peregrine management that "going it alone" is simply not possible. Hence, the numerous announcements regarding partnering. At the moment I don't think any serious partner is interested.
Their(and our) only hope for Bavi is if the small trials conducted by outside investigators show indisputable evidence in the clinics. Just my take.
GLTA, Paul
After the disaster of the Sunrise trial, Peregrine has moved forward with solid Avid growth and prudent efforts to salvage Bavi as part of the immunotherapy approach to cancer.
Spin it any way you like, Peregrine's much-maligned management clearly has a vision that could succeed. I hope 2017 will finally be the year we stop regretting our investment in Peregrine.
Ho, Ho, Ho, Paul
ststephensrevenge, I see no reason to believe Peregrine management's plans for Avid expansion are in any way related to the all but inevitable RS. In view of the high profit margin for Avid's products and services, I hope you are correct that we will soon see Avid 3, 4, 5 etc.
GLTA, Paul
Check out the Avid website. Very professional looking. I did a little googling of CDMOs. I saw enough to learn that CDMOs seem to be a coming thing. Revenues are expected to grow and US CDMOs seem to have solid place in it. Another point, from a revenue point of view Avid is not that small. Still another point, consolidation in this area seems likely.
Doesn't sound even a little like a scam, ROTFLMAO.
Paul
PPHM is not a scam. However, it has been a lousy investment.
Peregrine management IMO has tried very hard to make Bavi a success. Very promising in the lab. Not so good in the clinics.
They have tried very hard to make Avid a success. Avid is on a very promising trajectory so far.
Peregrine a scam? Ridiculous.
GLTA, Paul
Agreed, there is very little appetite in the market for PPHM shares based on anything less than stellar news. This may change, but it will take many quarters of strong performance from Avid and clinical Bavi success. The former looks likely, the latter not so clear.
Meanwhile, the reverse split looks inevitable. No way the share price moves up substantially under this circumstance.
GLTA, Paul
Peregrine forever! I thought the failure of the Sunrise trial would be the end of Peregrine, at least the end of all the activity here. Wrong, wrong, wrong.
As the latest CC revealed, Peregrine's burn rate is dropping to very low levels. Profitability is now expected in 18 months.
We all know if anyone can wrest failure from the jaws of victory, it's Peregrine. However, if Avid continues to grow and Bavi can carve out a profitable niche in the new immunotherapy approach to cancer, we could be here indefinitely.
GLTA, Paul
Avid is a successful and growing CDMO business generating significant revenue and one of our key goals going forward is to help ensure that its value is appropriately represented in the market cap of our overall business.
I wonder how Steve King and company expect to do this.
GLTA, Paul
Undervalued? If so, this should provide some comfort to shareholders, because the downside should be limited. OK, not very comforting.
So, the question for Steve King is: What can you do about it?
The simple answer is keep doing the things that make Peregrine valuable. Or, keep pushing Avid. Push Avid even harder.
Another thing King could do is be more open about Avid. If earnings of the first half came in over projections(I believe they did exceed the high end $55 million / 2 = 27.5), tell us why. If the year's revenue estimate is too low, give us a new one. If the second half earnings will be less than the first half, tell us why.
Come on King. If you don't think the market gives Peregrine an accurate value, maybe you need to tell our story better.
GLTA, Paul
Stoxx1, I don't think you need to worry much about Peregrine trying to move the anti-PS platform, including Bavi, on their own. Ever since the Sunrise crash, management has been on the partnering wavelength. I fear they are not very good at it, but they constantly say they want to partner whatever they have.
They clearly know they don't have the money to attempt any expensive programs. The market will not give them the money. Partnering is the only viable way to take anti-PS to the FDA and the drug stores.
We'll see.
GLTA, Paul
Peregrine is moving forward. No easy trick considering the huge disappointment of the Sunrise trial.
Thanks to Avid, Peregrine is growing financially stronger every quarter. Still on track for profitability in 18 months.
While Bavi has not achieved the success we hoped for, it is still alive. Sadly, we won't know how alive until the new clinical trials get underway. Sadder still these trials are not moving quickly. On the bright side as they are not company sponsored trials they are cheap.
Beyond Bavi and Avid, there are a few other Peregrine efforts underway but not visible enough to warrant featuring in the CC.
As a big loser on the share price, I understand the non-stop negativity here. However, anyone who hangs around might be rewarded. Maybe not very likely, but definitely possible.
GLTA, Paul
Record revenue, Bavi showing signs of life, burn rate $2 million. I am sitting on a huge loss, but I see hope for a turn around. Might not happen, but maybe it will.
In view of the revenue total for the first six months, I have to wonder why they didn't increase the expected total revenue for the year. Did they expect more revenue in the first half of the year?
GLTA, Paul
The anti-PS platform is only valuable if an effective anti-PS drug is found. Based on testing to date, Bavituimab has not proved it is The Anti-PS drug. Boy do we all wish it was.
Meanwhile, some other company may come up with The Anti-PS drug. If they do, they will have to pay Peregrine IMO based on Peregrine's extensive anti-PS intellectual property.
At least Avid is growing rapidly. Additionally, Bavituximab may have some place in the anti-PS arsenal. The next group of Bavi-immunotherapy trials might establish this.
GLTA, Paul
Groan, Sierra is back. Whoever they are, they never had any meaningful insight into Peregrine that I recall.
As to a revenue guess for Monday: if the annual total estimated is $55 million and the first quarter was $9 million, then on a prorate basis the 2nd quarter should be 27 - 9, or $18 million. Maybe we will get a nice surprise and come in over $20 million.
GLTA, Paul
Stoneroad, I have given up predicting price moves for Peregrine. I hope we see blow out revenue numbers on Monday. Otherwise, we will see the usual "sell on the news" move.
We'll see.
Paul
Earning surprise? Not to those of us who follow the Perils of Peregrine. Last quarter's revenue was largely deferred to this quarter due to a third party hiccup. Adding that revenue to this quarter's could be an impressive percentagewise bump. Enough to break even? Probably not, but close maybe.
GLTA, Paul
rev_mon, probably correct about a major partnership. Probably the only way to get back over a dollar without a RS. Not likely to happen soon enough to prevent the RS. However, not impossible.
It is somewhat comforting Peregrine management realizes the only way forward with Bavi is a partnership. We'll see.
GLTA, Paul
Profitable quarter for Peregrine? We know a chunk of Avid receipts for the last quarter were moved into this quarter due to a backup at a third party's operation. Will booking those receipts into this quarter along with this quarter's Avid receipts and the declining cost of operations push Peregrine temporarily into the black?
Maybe not, we'll see. Probably wouldn't be enough to get the share price back over a dollar, but might be a trading opportunity for the risk takers.
GLTA, Paul
Geo, I took a lot of abuse years ago when I said I would happily take $5 to 10 a share. Never got the chance.
$2 looks real good now, doesn't it? With a rapidly growing Avid and a possible Bavi comeback, $2 bucks may be possible next year.
GLTA, Paul
Where we are.
Not where we want to be.
1. Facing a reverse split, but the damage has been done. Always could get worse but probably no reason for it now.
2. Peregrine in solid financial shape. Cash in the bank and much reduced burn rate.
3. Avid still growing robustly.
4. Management still projecting sustained profitability in 21 months. Next quarter may be profitable due to that third party delay in the prior quarter's Avid receipts. Could give a nice bump.
5. Preclinical data shows Bavi not dead yet.
6. Clinical trials run through third parties should start up soon. Not sure how soon they might produce results.
Probably not much to see here for a while. As usual next year could be better.
GLTA, Paul
I don't see the new bavi-immunotherapy trials in clinicaltrials.gov. Wonder why not there yet?
GLTA, Paul
Last week's pre-clinical news? Was it very promising, somewhat promising or not promising at all? By the way we all know pre-clinical is not as significant clinical news.
TIA, Paul
Living the Bavi dream. Maybe we will. If we don't, I am with those of you who wonder what Avid alone could be worth by the end of the next calendar year and the year after that.
Gross annual sales could be $80 million assuming no receipts from the third facility in calendar 2017. Net profit maybe $15 million.
What level of market capitalization would this merit? We are currently about $80 million, aren't we?
2018 revenue could be $100 million. Net profit closer to $30 million.
What level of market capitalization would this merit?
So, if we hang around until December of 2018, what might out pre- RS shares be worth based on Avid alone?
Seems like a useful thing to consider.
GLTA, Paul
A very positive ESMO PR on Monday could generate a strong up move in the AM. Sadly, such a move would evaporate by closing, unless the news is truly extraordinary. Don't expect it, but you never know.
GLTA, Paul
itsabouttime, I believe Bavi value is resonating with BPs when one of them does a significant cash deal with Peregrine.
Don't see it in the next few months. Maybe next year. Sounds like the Chicago Cubs. I don't think we can wait as long as they have.
GLTA, Paul
We all knew we were headed for a RS. I railed against it, but short of a miracle partnership knew it was coming.
We all knew Avid was moving toward significant revenue and profits. A few more years of progress, and we might actually get our PPHM investments back in the black.
We didn't know Bavi had as much life left in it. It may still evaporate, but at the moment there is some reason to hope.
GLTA, Paul